AI in radiology: There’ll be an ‘app store’ for that

Radiology is the medical specialty most conducive to clinical AI applications. After all, the pre-AI technique of computer-aided detection has been used in mammography since 1998, for example. So it shouldn’t come as a surprise to find AI “app stores” rising in radiology.

The Harvard Business Review posted a piece looking at the development June 17.

Article co-authors Woojin Kim, MD, and Karen Holzberger, both executives with Nuance—which, it must be noted, is already in the “radiology app store” business—suggest that such AI marketplaces can serve two groups of stakeholders.

For doctors and hospitals, these marketplaces can offer one-stop shopping for an array of AI offerings. For AI developers, they can mean access to a well-defined target market and an end-user feedback channel.

“While AI marketplaces should foster widespread adoption of AI in radiology, they also have the potential to help alleviate radiologist burnout,” not least by improving the speed and quality of radiology reporting, Kim and Holzberger write.

“The recent emergence of AI marketplaces can accelerate the adoption of AI algorithms, helping to manage growing workloads while providing doctors with tools to improve diagnoses, treatments and, ultimately, patient outcomes.”

Read the whole thing:

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

FDA Commissioner Robert Califf, MD, said the clinical community needs to combat health misinformation at a grassroots level. He warned that patients are immersed in a "sea of misinformation without a compass."
 

With generative AI coming into its own, AI regulators must avoid relying too much on principles of risk management—and not enough on those of uncertainty management.

Cardiovascular devices are more likely to be in a Class I recall than any other device type. The FDA's approval process appears to be at least partially responsible, though the agency is working to make some serious changes. We spoke to a researcher who has been tracking these data for years to learn more. 

Trimed Popup
Trimed Popup